Score Overview
Explore the 2021 public Archive ranking β
Where Incyte Corporation has ranked, year by year
Showing 10 years ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- INCY
2004: 95.2% Β· 2021: 57.6% Β· free through 2021 Β· longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-11-17 | $ 119.09 | β |
1 Year2025-11-17 | $ 104.17 | 14.32% |
5 Years2021-11-17 | $ 65.02 | 83.16% |
10 Years2016-11-17 | $ 105.55 | 12.83% |
20 Years2006-11-17 | $ 5.36 | 22x |
30 Years1996-11-15 | $ 10.13 | 11x |
All Time1993-11-04 | $ 1.88 | 63x |
| Period | Last Price2026-11-17 | 1 Year2025-11-17 | 5 Years2021-11-17 | 10 Years2016-11-17 | 20 Years2006-11-17 | 30 Years1996-11-15 | All Time1993-11-04 |
|---|---|---|---|---|---|---|---|
| Price | $ 119.09 | $ 104.17 | $ 65.02 | $ 105.55 | $ 5.36 | $ 10.13 | $ 1.88 |
| Return | β | 14.32% | 83.16% | 12.83% | 22x | 11x | 63x |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 6.01B | $ 403M | $ 3.85B |
| 2025 | $ 5.14B | $ 1.28B | $ 3.58B |
| 2024 | $ 4.24B | $ 32M | $ 2.15B |
| 2023 | $ 3.69B | $ 597M | $ 3.65B |
| 2022 | $ 3.39B | $ 340M | $ 3.23B |
| 2021 | $ 2.98B | $ 948M | $ 2.34B |
| 2020 | $ 2.66B | -$ 295M | $ 1.80B |
| 2019 | $ 2.15B | $ 446M | $ 2.11B |
| 2018 | $ 1.88B | $ 109M | $ 1.43B |
| 2017 | $ 1.53B | -$ 313M | $ 1.16B |
| 2016 | $ 1.10B | $ 104M | $ 808M |
| 2015 | $ 753M | $ 6M | $ 707M |
| 2014 | $ 511M | -$ 48M | $ 600M |
| 2013 | $ 354M | -$ 83M | $ 509M |
| 2012 | $ 297M | -$ 44M | $ 228M |
| 2011 | $ 94M | -$ 186M | $ 277M |
| 2010 | $ 169M | -$ 31M | $ 424M |
| 2009 | $ 9M | -$ 211M | $ 470M |
| 2008 | $ 3M | -$ 178M | $ 198M |
| 2007 | $ 34M | -$ 86M | $ 256M |
| 2006 | $ 27M | -$ 74M | $ 318M |
| 2005 | $ 7M | -$ 103M | $ 344M |
| 2004 | $ 14M | -$ 164M | $ 469M |
| 2003 | $ 41M | -$ 166M | $ 293M |
| 2002 | $ 95M | -$ 136M | $ 429M |
| 2001 | $ 219M | -$ 183M | $ 507M |
| 2000 | $ 194M | -$ 29M | $ 582M |
| 1999 | $ 157M | -$ 26M | $ 66M |
| 1998 | $ 134M | $ 3M | $ 50M |
| 1997 | $ 90M | $ 6M | $ 51M |
| 1996 | $ 41M | -$ 6M | $ 7M |
| 1995 | $ 12M | -$ 9M | $ 10M |
| 1994 | -$ 11M | $ 6M | |
| IPO1993 | $ 300K | -$ 4M | $ 15M |

Incyte Corporation fundamental performance
Between 2005 and 2025, revenue grew from $ 7M to $ 5.14B and net income went from -$ 103M to $ 1.28B. Revenue increased in 18 of those 20 years; net income in 10.
Across Incyte Corporation's full reported history, from 1993 to 2025, revenue grew from $ 300K to $ 5.14B and net income went from -$ 4M to $ 1.28B. Revenue increased in 81% of the years measured; net income in 52%.
Incyte Corporation currently holds a 20-year HDB Score of 5.9 out of 10. How the HDB Score is calculated.
Membership
Continue INCYβs history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 5,187 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
Explore other companies
Healthcare Services Group IncHCSGΒ· revenue grew in 80% of years
McKesson CorporationMCKΒ· revenue grew in 95% of years
Laboratory Corporation of America HoldingsLHΒ· revenue grew in 90% of years
Tenet Healthcare CorporationTHCΒ· revenue grew in 70% of years
Dr. Reddyβs Laboratories Ltd ADRRDYΒ· revenue grew in 80% of years